EFFECT OF FLUOXETINE AND BROMOCRIPTINE ON CRAVING OCCURRING DURING WITHDRAWAL FROM ALCOHOL

SUDIPTO CHATTERJEE AND MOHAN K. ISAAC

SUMMARY

Craving is an integral element in the understanding of alcohol dependence. Recent human and animal research implicates the serotonergic and dopaminergic systems in the mediation of excessive alcohol consumption. In this study, a cue-based approach was used to qualitatively and quantitatively assess craving during acute withdrawal from alcohol. Fifty alcoholics were given either placebo, bromocriptine or fluoxetine in a randomised double-blind fashion and craving was sequentially measured over the next 15 days. Both fluoxetine and bromocriptine significantly attenuated total craving scores without similarly affecting withdrawal symptoms. The results suggest the importance of neurotransmitters in mediating craving. The significance of these data in the light of various behavioural and neurochemical models have been discussed.

INTRODUCTION

Most attempts at identifying common defining feature of alcoholism have invoked the concept of 'craving' as a key explanatory parameter. Despite the popularity of the term, perhaps due to its intuitive appeal, there is no consensual definition as indeed for 'urges' and 'wanting' which have been used interchangeably (Kozlowski & Wilkinson, 1987). Current consensus regards craving as a non-specific vector connected to the subjective desire to take drugs (Tiffany, 1990). It does not by itself define the various states that can potentially activate the desire.

In the search for the determinants of craving, the cue reactivity paradigm has been extensively used. This approach has demonstrated that for a group of alcoholics, various internal and external drug-related cues induce autonomic arousal (Glautier & Drummond, 1994). However, the subjective report of craving is a less consistent finding as casting doubt on the proposed linear relationship between arousal, craving and drug intake. Conditioning theories have traditionally been used to explain these results. Briefly, negative reinforcement (withdrawal-based) models view craving as a desire of relief from distressing overt or covert withdrawal symptoms (Koob and Bloom, 1988). Positive reinforcement (euphoria-based) theories perceive craving as the desire for the 'high' induced by alcohol (Stewart et al, 1984). Despite the limitations (Drummond et al, 1990), these theories have established a framework for the understanding and experimental induction of craving.

A biological basis for craving has been proposed from the observation that certain laboratory animals voluntarily and selectively consume alcohol in a manner similar to that of humans (Murphy et al, 1982). To explain this, all psychoactive drugs, including alcohol, are proposed to act on 'brain-reward systems' (Wise & Bozarth, 1987) altering them in crucial ways to maintain drug use. The ventral tegmental area (VTA) in the ventral midbrain and its projection to the nucleus accumbens (NA) have been identified as the crucial brain area in reward mediation (Robinson & Berridge, 1993). By virtue of being the major neurotransmitter input, the mesocorticolimbic dopamine (DA) system has been implicated in drug reinforcement (Wise and Romprei, 1989) since all abusable drugs share the common property of selectively enhancing DA release in the VTA-NA areas. Alcohol has also been found to increase DA release in these regions following local or systemic administration.
CRAVING IN ALCOHOL WITHDRAWAL

(Signs et al, 1992). In addition, DA agonists like bromocriptine have been found to attenuate drinking in animals and reduce craving in human subjects (Dongier et al, 1991) suggesting a strong dopaminergic modulation of the need to drink.

The serotonergic (5HT) system has also been implicated in the voluntary consumption of alcohol (Lemarquand et al, 1994). Various pharmacological manipulations increasing brain 5HT have been found to reduce consumption in animal models (Lu et al, 1993). Similarly, the use of specific serotonergic reuptake inhibitors (SSRI) like fluoxetine and zimeldine (Amit et al, 1991) have been observed to reduce craving and subsequent alcohol consumption in humans. All this suggests that hypofunctioning of the 5HT system may be relevant to the experience of craving.

The current study, based on the above findings, seeks to examine the effects of DA and 5HT function enhancement during acute withdrawal from alcohol. The hypothesis made was that augmentation of DA and 5HT by appropriate pharmacological tools would reduce craving.

METHOD

Subjects for the study were chosen from males presenting to the outpatient facilities of NIMHANS, Bangalore. After screening, prospective subjects were referred to assess eligibility of participation.

The following inclusion criteria were used to generate a relatively homogeneous population:

1. After a detailed clinical interview with the subject and a key relative, all patients had to unambiguously fulfill diagnostic criteria for alcohol dependence, as in the DSM - III R (APA, 1987).

2. Subjects had to be in the age group of 18 - 45 Years.

3. Only subjects presenting with simple withdrawal were chosen. To facilitate measurement and ensure drug compliance, subjects had to agree to be inpatients during the study period.

4. The manifestations of withdrawal from alcohol are 'time limited'. To achieve uniformity of measurement, all subjects had their last drink within 24 hours of participation in this study.

5. Presence of cognitive deficits was measured by the MMSE (McHugh & Folstein, 1978). Only subjects scoring above the suggested cut-off were selected.

6. Presence of concurrent depression and anxiety disorders was specifically sought for in the clinical interview. Only subjects without an obvious co-morbid depression anxiety were chosen.

7. Only subjects without serious alcohol-induced medical complications, as assessed by a detailed clinical examination and relevant investigations, were included in the trial.

Information regarding current age, age of onset, duration of drinking and the duration of dependence was also collected since each of these could affect the severity of the withdrawal reaction. The rationale of the study was also explained to the subjects and informed consent for participation obtained.

Measurement of craving

In view of the many limitations inherent in the measurement of craving, 33 alcoholics were asked about common internal and external correlates of the perceived subjective desire to drink during the experience of withdrawal. After content analysis, the 10 most common responses were identified. These included various internal subjective states as well as cues related to the environment. These items together formed the Scale for assessment of alcohol withdrawal-related craving (see Appendix). To quantify the severity of each item, a ten-point subject-rated visual analogue scale was used.

Measurement of withdrawal

The phenomenology and severity of withdrawal was assessed by the Scale for alcohol withdrawal. This is a 22-item instrument, and each item is graded on a 0-3 scale of severity.

In keeping with the hypothesis, fluoxetine and bromocriptine were chosen to explore the
**DEPNON**

**Begins to change the picture immediately**

**Unique therapeutic benefits**

- Immediate sleep improvement
- Rapid relief of anxiety and agitation
- Established antidepressant efficacy
- Virtually no anticholinergic side-effects
- Significant safety in overdose

---

**COMPOSITION**

**DEPNON** 10 mg

Each film-coated tablet contains:
- Mianserin Hydrochloride : BP 10 mg

**DEPNON** 30 mg

Each film-coated tablet contains:
- Mianserin Hydrochloride B.P. 30 mg

**INDICATIONS** For relief of symptoms of depression in those cases of depressive illness where drug therapy is indicated

**PRESENTATION** 10 x Blister pack of 10 tablets

For characteristics, dosage administration, warnings and precautions, interactions, adverse reactions, overdose, storage etc. Refer infar Pack insert

---

© Geimler RH. Experiences with Tofranil (Depnond in the treatment of depression in out-patients. Therapiewoche 1981; 31: 4075-4077
RAJSON RECORDING PAPERS

(A House of Precision Graph Thermal and E.E.G. PAPERS)

CONTACT FOR

E.E.G. PAPERS

(Side name Printing & Logo Printing also done)

Also Available
ULTRA SOUND THERMAL PAPER
All Types of T.M.T. Paper
Video Cassattes for ECHO
All types and all size of Thermal Paper
CONTACT AT

RAJSON RECORDING PAPERS

31, Civil Street, Ghumar Mandi,
Ludhiana - 141 001 (Punjab)
Phones - 0161-37265,20470
Pager No. 0161-9612-120115
effects of 5HT and DA system perturbation on experienced craving.

STUDY DESIGN

Subjects were randomly allocated to any one of three groups receiving either fluoxetine, bromocriptine or placebo. Fluoxetine was used at a dose of 40 mg/day, while 5 mg of bromocriptine was administered and glucose powder was the placebo. All groups were given the drugs thrice a day in identical capsules. The active drugs were administered in the morning and afternoon with the night dose being a placebo capsule. The allocation of patients and subsequent drug administration was done in a double-blind fashion.

On Day 0, both withdrawal and craving - scale items were administered and rated. After this, drugs were started and continued for the next 15 days. Scale items were assessed each day and those found positive were rated for severity.

STATISTICAL TECHNIQUES

1. Descriptive statistical measures like mean and SD were used to describe pre-treatment sample characteristics.

2. Two-way ANOVA (days x drugs) were performed for each item and for the total craving scores between the three groups.

3. The craving - scale items were subjected to principal component analysis with varimax rotation to generate higher-order factors.

4. Two-way ANOVA was also performed for total withdrawal - scores between the three groups.

5. Post-hoc Fisher's 't' test of significance was carried out for each craving - scale item.

6. Correlation analysis was done between craving and withdrawal items on Day 0.

RESULTS

After initial screening, 50 subjects entered the trial. On opening the blind the group receiving the placebo had 18 subjects, whereas the groups receiving fluoxetine and bromocriptine had 16 subjects each.

Table 1 displays the pretreatment values of variables like age, age of onset of drinking, duration of alcohol use and duration of dependence. There were no significant differences on any of these variables across the groups.

The principal component analysis of the craving - scale items (Table 2) led to the emergence of three meaningful principal components which together explained 61.2% of the variance. These were labelled as (1) restoration of bodily comfort, (2) alleviation of negative mood state and (3) responsivity to external cues.
Table II
Principal components analysis of craving-scale items with varimax rotation.

| Item     | Evols | PC 1: | PC 2: | PC 3: |
|----------|-------|-------|-------|-------|
|          |       | Weights | Weights | Weights |
| Morning  | 30.82 | 0.39   | 0.16   | 0.33   |
| Thirst   | 13.32 | 0.31   | 0.08   | 0.08   |
| Fatigue  | 10.71 | 0.35   | 0.10   | 0.27   |
| Irritability | 9.38 | 0.17   | 0.61   | 0.27   |
| Anxiolysis | 7.86 | 0.39   | 0.61   | 0.27   |
| Insomnia | 6.75  | 0.24   | 0.16   | 0.26   |
| Wine store | 4.76 | 0.18   | 0.26   | 0.32   |
| Tremors  | 3.29  | 0.37   | 0.22   | 0.05   |
| Smoking  | 2.88  | 0.37   | 0.25   | 0.38   |
| Food     | 2.24  | 0.21   | 0.02   | 0.65   |

The three principal components that emerged were:
1. Restoration of bodily comfort
2. Alleviation of negative mood state
3. Responsiveness to external cues

The three principal components that emerged were:
1. Restoration of bodily comfort
2. Alleviation of negative mood state
3. Responsiveness to external cues

Table III
Two-way ANOVA for individual craving-scale items

| Item     | Drug f | Drug p* | Days f | Days p* | Interaction f | Interaction p* |
|----------|--------|---------|--------|---------|--------------|----------------|
| Morning  | 115.93 | 0.001   | 206.87 | 0.001   | 7.28         | 0.001          |
| Thirst   | 18.93  | 0.001   | 51.50  | 0.001   | 1.73         | 0.009          |
| Fatigue  | 80.33  | 0.001   | 180.59 | 0.001   | 6.07         | 0.001          |
| Irritability | 5.35 | 0.005   | 22.46  | 0.001   | 1.40         | 0.076          |
| Anxiolysis | 102.58 | 0.001 | 157.72 | 0.001 | 6.16 | 0.001 |
| Insomnia | 91.76  | 0.001   | 107.39 | 0.001   | 6.30         | 0.001          |
| Wine store | 5.87  | 0.003   | 53.89  | 0.001   | 2.00         | 0.001          |
| Tremors  | 104.55 | 0.001   | 235.76 | 0.001   | 5.75         | 0.001          |
| Smoking  | 40.97  | 0.001   | 36.82  | 0.001   | 2.69         | 0.001          |
| Food     | 3.36   | 0.035   | 35.86  | 0.001   | 0.67         | 0.910          |

* Significance at P < 0.001 Degrees of freedom: 2, 49

The two-way ANOVA scores for individual craving-scale items are displayed in Table 3. The items showing statistically significant day x drug interactions tapped craving related to early morning hangovers, fatigue, anxiolysis, insomnia, tremors and in responses to pleasurable external cues like preferred wine store and smoking.

The total craving - scores between the groups are shown in Figure 1. Figure 2 graphically depicts total scores for the withdrawal items.

The correlation analysis of craving- and withdrawal-scale items was performed for Day 0 to understand the extent of overlap of the constructs (data not shown, available on request). The only meaningful correlations occurred between irritability as a cue and withdrawal symptoms of insomnia, restless sleep, tremors and dehydration.
DISCUSSION

In this study, we chose to investigate craving occurring during withdrawal as it is consistent, vivid and therefore, more amenable to measurement. Secondly, the potential effects of drugs are expected to be more comprehensible since neurotransmitter changes during withdrawal have already been relatively well documented (Nutt and Glue, 1986).

There is a lack of consensus regarding which strategy best identifies craving. In view of this, a 'bottom-up' approach was chosen with alcoholics' self-reports forming the basis for the measurement of craving. This ensures that the dimensions of craving are tapped adequately as demonstrated by adequate face validity and sensitivity of the craving-scale items.

To generate higher-order factors which are closer to the psychological structure of craving, multivariate statistics like principal components analysis were used. To this end three clinically meaningful factors explaining 61.2% of the variance were generated. Factor 1 (restoration of physical comfort) and Factor 2 (alleviation of negative mood) could conceptually be collapsed into a single 'relief from distress' factor. Factor 3, however, was more closely linked to the positive expectancy effects of alcohol.

A large body of work sees craving as arising predominantly from the substrate of withdrawal distress (Laberg & Ellertsen, 1987). Alcohol, by removing this distress, has been thought to have a negative reinforcing relationship with craving. In view of the current study being conducted during acute withdrawal, this negative reinforcement relationship was expectedly observed especially with cues tapping the physical symptoms of withdrawal.

Positive expectancy-related cues, as a determinant of craving occurring during a period of distress, is an interesting finding. It suggests that the desire for euphorogenic effects of alcohol are intermingled with, but independent of, the need to relieve distress. The opponent-process theory of alcohol use can explain this observation best (Donovon & Chaney, 1985). This theory suggests that drugs simultaneously elicit mutually inhibitory agonist and antagonist responses. Depending on the context, any one response could assume a greater, but not exclusive, role in determining further drinking. Since withdrawal-related craving was studied, it explains both why drug antagonistic (withdrawal) cues assume greater importance and how agonist (euphoric) responses could coexist.

It is noteworthy that a large part of the variance of the observed results remained unexplained. Conceivably, this could be a function of the study setting, quality of therapeutic alliance, sick-role expectations and personality variables. None of these have been adequately studied and remain an important area for further research.

The double-blind design of the study, use of a placebo group, clear specification of the dependent status, prevention of drop-outs and adequate compliance with experimental drugs are in keeping with the expected methodological standards (Moskowitz, 1983). In addition, the pre-treatment variables were homogeneously distributed across groups thus increasing the robustness of the findings.

The incorporation of the placebo group makes naturalistic observation of the patterns of withdrawal and craving possible. As seen in Diagrams 1 and 2, total scores decline in a fairly similar fashion. However, both active drugs affected craving and withdrawal differentially. Both bromocriptine and fluoxetine produce significantly greater detriment of craving scores as compared to the effects on withdrawal symptoms. Again, between drugs, unlike in withdrawal, fluoxetine produced greater effects between days 3 to 9 on total craving scores. This dissociation of drug effects on craving and withdrawal suggest that the neurobiological substrates of craving are distinct from those mediating withdrawal. Moreover, correlation analysis between craving- and withdrawal-scale items, done on Day 0, do not show significant overlap, again suggesting their relative independence.
There is a large body of evidence linking 5HT dysfunction and alcohol consumption. Preclinical studies have mostly shown an inverse relationship between alcohol preference and 5HT levels have been demonstrated in crucial brain areas like the VTA and NA in alcohol-prefering rats even before exposure to alcohol (Murphy et al, 1982). Interestingly, alcohol increases 5HT in these areas following both acute and chronic exposure, prompting the self-medication hypothesis of alcohol use (Haleem 1990). Clinical extension of these results with various SSRIs which increase synaptic availability of 5HT are found to attenuate craving and alcohol consumption (Gill & Amit, 1989).

This study adds to the growing body of research linking 5HT and craving. It confirms that the postulated inverse relationship holds true even during withdrawal. During acute withdrawal, there is a fall in 5HT levels in the absence of alcohol (Yamamura et al, 1992). This is probably corrected by fluoxetine by producing a specific increase of 5HT in a non-selective manner. The rapid onset of action would suggest that these are independent of fluoxetine's anti-depressant effect. The significantly greater efficacy of fluoxetine would argue against the proposed indirect enhancement of DA in the brain-reward areas as being the primary mode of action (Blandina et al, 1989).

Specific 5HT enhancement thus emerges as the most probable mechanism of fluoxetine's ability to reduce craving. The next logical phase of research would be to identify which specific 5HT receptor subtypes mediate this effect. The 5HT3 receptor has emerged as a likely candidate in this regard (Grant & Barrett, 1991). Similarly, the demonstration that m-chlorophenylpapaverine (mCPP), a 5HT agonist with some specificity for 5HT2a and 5HT2c receptors, could elicit alcohol-like high in abstinent subjects is a direct demonstration of the link between 5HT and craving (Krystal et al, 1994). This approach would also clarify whether 5HT deficits in alcoholism are unique to the disorder or is a more general marker of psychopathology as has been suggested (Virkkunen et al, 1994).

The other hypothesis made was that bromocriptine by its specific D2 agonism would reduce craving. This has also been substantiated by the results of this study. Neuroleptic-induced dysphoria and related animal work have suggested that DA mediates hedonic properties of cues. This is achieved by attribution of positive salience thus making these cues more attractive and wanted (Robbins & Everitt, 1992). As an extension of this, drugs are supposed to be reinforcing because of their property of increasing DA in brain-reward areas. During the process of withdrawal, there is a global reduction of DA (Kuriyama & Okhuma, 1991) probably producing distress and therefore craving. According to this hypodopaminergic theory of craving, bromocriptine probably produces its effects by substituting for the lowered DA.

Direct DA agonism, in spite of its strong theoretical link with drug use, was found to be less effective than fluoxetine at least initially. The reason for this remains unclear. It might be a consequence of the dose of bromocriptine used (5 mg/day) which would cause D2 autoreceptor stimulation, thus lessening the magnitude of post-synaptic agonistic effects (Fuxe et al, 1981).

In conclusion, this study measures craving in relation to withdrawal from alcohol and explores the effect fluoxetine and bromocriptine have on it. It also adds to the evidence linking craving and certain monoamine (DA and 5HT) levels. In addition to discussing the possible mechanisms underlying these findings, this work suggests new approaches for a more comprehensive understanding and probable therapeutic manipulation of the compelling experience of drug craving.

REFERENCES

American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (3rd edn. revised) (DSM-IIIR).
Washington, D.C.: American Psychiatric Association.

Amit, Z., Smith, B.R., & Gill, K. (1991) Serotonin uptake inhibitors: effects on motivated consummatory behaviours. Journal of Clinical Psychiatry, 52, 55-60.

Blandina, P., Goldfarb, J., Caddock-Royal, B. & Green, J.P. (1989) Release of endogenous dopamine by stimulation of 5HT3 receptors in rat striatum. Journal of Pharmacology and Experimental Therapeutics, 251, 803.

Dongier, M., Vachow, L. & Schwartz, G. (1991) Bromocriptine in the treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research, 15, 970-977.

Donovan, D.M. & Chaney, E.F. (1985) Alcoholic relapse prevention and intervention: models and methods. In Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors, (eds. G.A. Marlatt & J.R. Gordon). New York: Guildford.

Drummond, C.D., Cooper, T. & Glautier, S.P. (1990) Conditioned learning in alcohol dependence: implications for the exposure treatment. British Journal of Addiction, 85, 725-743.

Fuxe, K., Agnati, L., Kohler, C., Kuonen, D., Ogren, S., Andersson, E. & Hokfelt, T. (1981) Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides. Journal of Neural Transmission, 51, 3-37.

Gill, K. & Amit, Z. (1989) A review of clinical studies of alcohol consumption using serotonin-reuptake inhibitors. Alcoholism: Clinical and Experimental Research, 13, 37-51.

Glautier, S.P. & Drummond, C. (1994) Alcohol dependence and cue reactivity. Journal of Studies on Alcohol, 55, 224-229.

Grant, K.A. & Barrett, J.E. (1991) Blockade of the discriminative stimulus effects of ethanol with 5HT3 antagonists. Psychopharmacology, 104, 451-456.

Haleem, D.J. (1990) Injected tryptophan increases brain but not plasma tryptophan levels more in ethanol-treated rats. Life Science, 47, 971-979.

Imperato, A. & Dichiara, G. (1986) Preferential stimulation of dopamine release in the nucleus accumbens of freely-moving rats by ethanol. Journal of Pharmacology and Experimental Therapeutics, 239, 219-228.

Koo, G.F. & Bloom, F.E. (1988) Cellular and molecular mechanisms of drug dependence. Science, 242, 715-723.

Kozolowski, L.T. & Wilkinson, D.A. (1987) Use and misuse of the concept of craving by alcohol, tobacco and drug researchers. British Journal of Addiction, 82, 31-36.

Krystal, J.H. Webb, E., Cooney, A.N., Kranzler, H.R. & Charney, D.S (1994) Specificity of ethanol-like effects elicited by serotonergic and noradrenergic mechanisms. Archives of General Psychiatry, 51, 898-911.

Kuriyama, K. & Okhuma, S. (1991) Alterations in the function of cerebral neurotransmitters during establishment of alcohol dependence: neurochemical aspects. Alcohol and Alcoholism, 24, 239-249.

Laberg, J.C. & Ellertsen, B. (1987) Psychophysiological indicators of craving in alcoholics: effects of cue exposure. British Journal of Addiction, 82, 1341-1348.

Lamarquand, D., Pihl, R.O. & Benkelfat, C. (1994) Serotonin and alcohol intake, abuse and dependence: clinical evidence. Biological Psychiatry, 36, 326-337.

Lu, M.R., Wagner, G.C., & Fisher, H. (1993) Ethanol consumption following acute fenfluramine, fluoxetine and dietary tryptophan. Pharmacology, Biochemistry and Behaviour, 44, 931-937.

McHugh, P.R. & Folstein, M.F. (1978) Mini Mental State Examination: a convenient tool for describing cognitive state in patients. Psychiatric Research, 12, 189-198.

Moskowitz, G. (1983) Deficiencies of clinical trials of alcohol withdrawal. Alcoholism: Clinical and Experimental Research, 7, 42-46.

Murphy, J.M., McBride, W.J., Lumeng, L. & Li, T.K. (1982) Regional brain levels of
monoamines in alcohol-preferring and non-preferring line of rats. Pharmacology, Biochemistry and Behaviour, 16, 145-149.

Nutt, D. & Glue, P. (1986) Monoamines and alcohol. British Journal of Addiction, 81, 327-338.

Robbins, T.W. & Everitt, B.J. (1992) Functions of dopamine in dorsal and ventral striatum. Seminars in Neuroscience, 4, 119-127.

Robinson, T.E. & Berridge, K.C. (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews, 18, 247-291.

Sellers, E.M., Higgins, G.A. & Sobell, M.B. (1992) 5HT and alcohol abuse. Trends in Pharmacological Sciences 13, 69-75.

Signs S.A ; Yamamoto, B.K & Schechter, M.D (1992) Invivo electrochemical determination of extracellular dopamine in the candate of freely-moving rats after a low dose of ethanol. Neuropharmacology, 26, 1653-1656.

Stewart, J., de wit, H. & Eibelboom, R. (1984) Role of unconditioned and conditioned drug effects in the self administration of opiates and stimulants. Psychological Review, 91, 251-268.

Tiffany, S.T. (1990) A cognitive model of drug urges and drug-use behaviour: role of automatic and non-automatic processes. Psychological Review, 97, 147-168.

Virkkunen, M., Rawlings, R., Tokola, R., Poland, R.E., Guidotti, A., Nemeroff, C., Bissett, G., Kalogeris, K., Karonen, S. & Linnoila, M. (1994) CSF biochemistries, glucose metabolism and diurnal activity rhythms in alcoholic, violent offenders, fire-setters and normal volunteers. Archives of General Psychiatry, 51, 20-27.

Wise, R.A. & Bozarth, M.A. (1987) A psychomotor theory of addiction. Psychological Review, 94, 469-492.

Wise, R.A. & Romprei, P.P (1989) Brain dopamine and reward. Annual Review of Psychology, 40, 191-225.

Yamamura, T., Hishida, S., Hatake, K., Taniguchi, T. & Ouchi, H. (1992) Effects of methamphetamine and ethanol on learning and brain neurotransmission in rats. Pharmacology, Biochemistry and Behaviour, 42, 389-400.

APPENDIX

1. When you wake up in the morning with a hangover, do you feel like having a drink immediately?

2. When you are feeling hot and thirsty, does the thought of having a drink come to mind?

3. When you are tired and exhausted, do you want a drink to feel better?

4. Whenever you are angry with somebody, do you have the urge to drink at once?

5. When feeling tense and anxious, do you feel like having a drink?

6. When unable to sleep at night, do you have a strong wish to drink?

7. When you see your usual wine store, do you feel attracted towards it for a quick drink?

8. When your hands shake, does the thought of a drink come to mind?

9. While smoking, do you also experience the desire to drink?

10. Just before your favourite meal, do you get an urge to drink?

Sudipto Chatterjee M.D., Senior Resident *; Mohan K. Isaac M.D., Additional Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore - 560 029.

* Corresponding author.